Skip to main content

Table 1 Comparison of clinical characteristics in patients with de novo DLB and PD

From: Comparisons of cardiovascular dysautonomia and cognitive impairment between de novo Parkinson’s disease and de novo dementia with Lewy bodies

Item PD (N = 75) DLB (N = 24) p value a
Age (years) 72.2 ± 9.4 80.0 ± 5.0 0.001
Gender (male/female) 27/48 18/6 0.001
Symptom duration (years) 1.6 ± 1.6 1.9 ± 1.7 0.296
UPDRS motor score 20.3 ± 10.9 21.3 ± 10.8 0.236
Subtype (akinetic-rigid/tremor-dominant or mixed) 45/30 19/5 0.087
Olfaction 4.1 ± 2.8 2.4 ± 2.2 0.010
Mini-mental state examination 27.7 ± 2.2 20.0 ± 4.7 0.001
Frontal assessment battery 15.1 ± 2.8 10.2 ± 3.4 0.001
MIBG H/M ratio delay 1.44 ± 0.33 1.22 ± 0.39 0.001
BP fall in head-up tilt-table test (HUT) (mmHg) 23.6 ± 20.0 48.5 ± 23.6 0.001
Prevalence of OH (−/+) 36/39 1/23 0.001
Norepinephrine at rest in supine position in HUT (μg/ml) 217.9 ± 88.2 172.8 ± 82.5 0.009
Nocturnal fall in BP in ABPM (%) 8.5 ± 9.4 −4.4 ± 12.6 0.001
ABPM type (dipper/non dipper or riser type) 37/38 4/20 0.005
BP fall in postprandial hypotension (mmHg) 18.4 ± 13.1 32.8 ± 17.2 0.001
Postprandial hypotension (−/+) 42/33 6/18 0.008
BP in supine hypertension (mmHg) 134.8 ± 21.5 147.5 ± 19.2 0.011
Supine hypertension (−/+) 45/30 10/14 0.116
Neurogenic supine hypertension (−/+) 56/19 12/12 0.013
Constipation (−/+) 25/50 1/23 0.008
  1. a Wilcoxon rank sum test and Lepage analysis for continuous variables and χ2 test for binary variables
  2. UPDRS Unified Parkinson’s Disease Rating Scale, MIBG 123I-metaiodobenzylguanidine, H/M: ratio of the average pixel count in the heart (H) to that in the mediastinum (M), ABPM 24-h ambulatory blood pressure monitoring